What is Dasatinib?

Category: Prescription Drugs

Most popular types: Sprycel


Dasatinib, brand name Sprycel®, is a tyrosine kinase inhibitor used to treat Ph+CML and Ph+ALL when resistance or intolerance develops to prior therapy. It targets most imatinib-resistant BCR-ABL mutation by distinctly binding to ABL-kinase to halt the proliferation of leukemia cells.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Chronic myeloid leukemia 15 11
Acute lymphocytic leukemia 7 0
Adenocarcinoma (non-small cell lung cancer) 1 0
Participate in clinical trial 1 0

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 5
Mild 5
None 1

Commonly reported side effects and conditions associated with Dasatinib

Side effect Patients Percentage
Headaches 2
Pleural effusion 2
Anxious mood 1
Black stool 1
Bone pain 1
Dizziness 1

Show all 16 reported side effects


Based on patients currently taking Dasatinib

Dosage Patients Percentage
100 mg daily 1

Why patients stopped taking Dasatinib

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 2
Doctor's advice 1
See all 2 patients who've stopped taking Dasatinib


Currently taking Dasatinib

Duration Patients Percentage
1 - 2 years 1

Stopped taking Dasatinib

Duration Patients Percentage
1 - 2 years 1
2 - 5 years 1
Adherence Evaluations Percentage
Always 11
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 2
Not at all hard to take 9
Cost per month
Cost per month Evaluations Percentage
$200+ 1
$100-199 0
$50-99 0
$25-49 0
< $25 3
Not specified 7

What people switch to and from

Patients started taking Dasatinib after stopping:

Treatment Patients Percentage
Imatinib (Gleevec) 3

Patients stopped taking Dasatinib and switched to:

Treatment Patients Percentage
Nilotinib (Tasigna) 1
Last updated:
There are no evaluations for Dasatinib.